International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 03 ISSUE 08 Pages: 5-8
SJIF IMPACT FACTOR (2021: 5.478) (2022: 5.636) (2023: 6.741)
OCLC – 1368736135

Journal Website: http://sciencebring.com/index.php/ijasr

Research Article

STRATEGIES FOR MANAGEMENT AND PREVENTION OF DRUG-INDUCED END-STAGE RENAL DISEASE

Submission Date: July 28, 2023, **Accepted Date:** Aug 02, 2023,
Published Date: Aug 07, 2023
Crossref doi: https://doi.org/10.37547/ijasr-03-08-02

Gagan Mittal
Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, Meerut, U.P., India

ABSTRACT

Drug-induced end-stage renal disease (ESRD) is a significant and potentially preventable cause of renal failure. This review explores various strategies for the management and prevention of drug-induced ESRD. Drugs, both prescription and over-the-counter, can lead to nephrotoxicity, acute kidney injury, and chronic kidney disease, ultimately progressing to ESRD. Understanding the mechanisms of drug-induced kidney injury is crucial in identifying high-risk medications and patient populations. The review highlights the importance of drug monitoring, dose adjustments, and renal function assessment to minimize the risk of drug-induced ESRD. Additionally, it discusses the role of healthcare providers in promoting medication safety and educating patients about potential renal risks. Furthermore, preventive measures, such as drug selection algorithms and pharmacogenetic testing, are explored to tailor drug therapies based on individual patient profiles. This review aims to raise awareness among healthcare professionals and patients about the importance of vigilant medication management and personalized approaches to mitigate drug-induced ESRD.

KEYWORDS

Drug-induced end-stage renal disease, nephrotoxicity, acute kidney injury, chronic kidney disease, medication management, drug monitoring, dose adjustment, renal function assessment, medication safety, drug selection algorithms, pharmacogenetic testing, personalized medicine, prevention, healthcare providers, patient education.

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 03 ISSUE 08 Pages: 5-8
SJIF IMPACT FACTOR (2021: 5.478) (2022: 5.636) (2023: 6.741)
OCLC – 1368736135

INTRODUCTION

Drug-induced end-stage renal disease (ESRD) is a growing concern in clinical practice, posing a significant challenge to healthcare providers and patients alike. The kidneys play a vital role in drug metabolism and excretion, making them susceptible to drug-related injury. Drug-induced nephrotoxicity, acute kidney injury (AKI), and chronic kidney disease (CKD) can all contribute to the progression of ESRD, resulting in substantial morbidity and mortality. Addressing the management and prevention of drug-induced ESRD is of utmost importance to optimize patient outcomes and reduce the burden on healthcare systems.

Various factors contribute to drug-induced renal injury, including drug-specific properties, patient characteristics, drug interactions, and comorbidities. Identifying high-risk medications and patient populations is essential in formulating effective strategies to minimize the occurrence and severity of drug-induced ESRD. This review aims to explore current approaches for the management and prevention of drug-induced ESRD, emphasizing the importance of medication management, drug monitoring, dose adjustments, renal function assessment, and personalized medicine in mitigating this renal risk.

METHOD

To conduct this comprehensive review, a systematic search of scientific literature was performed. A thorough examination of electronic databases, such as PubMed, Scopus, and Web of Science, was undertaken to identify relevant studies, articles, and reviews related to drug-induced ESRD and its management and prevention. The search was not limited by language and covered literature up to the present date.

The selected literature encompassed studies investigating drug-induced nephrotoxicity, AKI, CKD, and ESRD. Both experimental and clinical studies were included to provide a comprehensive understanding of the mechanisms involved in drug-induced renal injury. Additionally, publications addressing medication management, drug monitoring, dose adjustments, and renal function assessment in the context of drug-induced ESRD were incorporated.

The review also considered articles related to personalized medicine, pharmacogenetic testing, and individualized drug selection algorithms to tailor drug therapies based on patient-specific factors and genetic profiles. Preventive measures and best practices in medication safety and patient education regarding renal risks were also explored.

The findings from the selected literature were analyzed, synthesized, and organized to present a comprehensive overview of the strategies for managing and preventing drug-induced ESRD. The review aims to provide valuable insights for healthcare providers, researchers, and

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 03 ISSUE 08 Pages: 5-8
SJIF IMPACT FACTOR (2021: 5.478) (2022: 5.636) (2023: 6.741)
OCLC – 1368736135

policymakers, emphasizing the significance of vigilant medication management and personalized approaches to enhance renal safety and improve patient outcomes.

Results

The comprehensive review on strategies for the management and prevention of drug-induced end-stage renal disease (ESRD) revealed several important findings. Drug-induced nephrotoxicity, acute kidney injury (AKI), and chronic kidney disease (CKD) are significant contributors to the development of end-stage renal disease, placing a substantial burden on patients and healthcare systems. Various medications, both prescription and over-the-counter, have been associated with renal injury, highlighting the importance of vigilant medication management.

Discussion

The review highlighted the critical role of drug monitoring and renal function assessment in identifying early signs of drug-induced renal injury. Regular monitoring of renal function allows for timely detection of changes in kidney function, prompting appropriate interventions, such as dose adjustments or discontinuation of nephrotoxic medications. Healthcare providers play a crucial role in ensuring that medications are prescribed at appropriate doses, especially in patients with impaired renal function.

Moreover, personalized medicine emerged as a promising approach to prevent drug-induced ESRD. Pharmacogenetic testing can help identify patients with genetic variations that may predispose them to adverse drug reactions, including renal toxicity. Tailoring drug therapies based on individual patient profiles can reduce the risk of drug-induced renal injury and improve treatment outcomes.

The review also emphasized the importance of medication safety and patient education. Healthcare providers should educate patients about the potential renal risks associated with certain medications and the importance of adhering to prescribed doses. Empowering patients with knowledge about their medications and their impact on renal health can lead to improved medication adherence and early recognition of adverse effects.

Preventive measures, such as drug selection algorithms, can guide healthcare providers in choosing medications with a lower risk of renal toxicity when treating patients with pre-existing kidney conditions or those at higher risk for drug-induced renal injury.

Conclusion

In conclusion, drug-induced end-stage renal disease is a significant clinical concern that requires a multifaceted approach for effective management and prevention. Strategies such as drug monitoring, dose adjustments, renal function assessment, personalized medicine, and medication safety education can collectively reduce the incidence and severity of drug-induced ESRD. By implementing these strategies, healthcare providers can optimize patient care

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 03 ISSUE 08 Pages: 5-8
SJIF IMPACT FACTOR (2021: 5.478) (2022: 5.636) (2023: 6.741)
OCLC – 1368736135

and improve renal outcomes, ultimately contributing to better overall patient health and well-being. Additionally, further research in this area is warranted to identify novel therapeutic targets and refine existing strategies to combat drug-induced renal injury and its progression to end-stage renal disease.

REFERENCES

1. Kellum JA, Levin N, Bouman C, Lameire N. Curr Opin Crit Care, 2002;8:509-514.
2. Mehta RL, Chertow GM. J Am Soc Nephrol, 2003; 14:2178-2187.
3. Whelton A. Am J Med, 1999; 106:13S-24S.
4. Han WK, Bailly V, Abichandani R. Kidney Int, 2002; 62:237-244.
5. Baliga R, Ueda N, Walker PD, Shah SV. Drug Metab Rev, 1999; 31:971-997.
6. Swan SK. Semin Nephrol, 1997; 17:27-33.
7. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Semin Nephrol, 1997; 17:15-26.
8. Solomon R.. Kidney Int, 1998;53:230-242.
9. 9. Murphy SW, Barrett BJ, Parfrey PS. J Am Soc Nephrol, 2000; 11:177-182.
10. Waybill MM, Waybill PN. JV asc Intervent Radiol, 2001; 12:3- 9.
11. Kintzel PE. Drug Saf, 2001; 24:19-38.